News

ALTU-238 is being developed as a subcutaneously administered, long acting formulation of recombinant human growth hormone that employs Altus’s proprietary protein crystallization and formulation technology, for patients with

In this new position, Dr Skowronski will be responsible for development and execution of clinical protocols and providing medical input and review of clinical development strategy. Prior to

Mr Hanlon was previously vice president of R&D for Boston Scientific’s neurovascular division, where he oversaw a 100-person multi-disciplinary department and numerous successful product launches. Prior to Boston

Prior to her appointment as president and CEO, Ms Popovits served as president and COO since joining Genomic Health in February 2002, and as a director since March

An additional $12 million of BioThrax revenue originally planned for the fourth quarter of 2008 is projected to be recognized in 1Q 2009. This additional revenue is attributable

The $25 million upfront payment to Depomed under the agreement is due 60 days following completion of the Hart-Scott-Rodino Antitrust Improvements Act (HSR) review. Under the terms of

An additional approximately $267 million, or $3 per Indevus share, in cash will be payable in the future upon achievement of certain regulatory and sales milestones. The transaction

Cerepro was originally filed for marketing approval under exceptional circumstances in late 2005 and was reviewed by the European Medicines Regulatory Agency (EMEA) with reliance on Phase II

The collaboration which has been renewed several times and initiated in December 2002 focuses on the identification, development and commercialization of drugs for the treatment of neurodegenerative diseases,